Jets, Garrett Wilson agree to massive four-year contract extension
The New York Jets and their star wide receiver have agreed to a four-year contract extension. The new deal is worth $130 million with $90M of that guaranteed, according to NFL Network's Ian Rapoport:
In addition to the guarantees there are: a $13.75M singing bonus, a $20M option bonus in the second year and a $10M option bonus in Year 3.
While Wilson enters 2025 with two years still remaining on his rookie contract, the Jets wanted to make sure he was kept around New York for a much longer time than that. Now he's with the Jets through the 2030 season.
The 24-year-old is coming off his third straight 1,000-yard season since he was selected No. 10 overall in the 2022 NFL draft out of Ohio State. Wilson has had these positive years despite his poor quarterback play, which is why Jets want to keep him in the building.
With Wilson's deal finished, attention now turns to the team getting cornerback Sauce Gardner signed to an extension.
Jets Wire will continue to provide updates throughout the 2025 offseason.
This article originally appeared on Jets Wire: Jets, WR Garrett Wilson agree to four-year, $130 million extension
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
a minute ago
- Yahoo
Merck (MRK) as a Reliable Dividend Player in the Dogs of the Dow Lineup
Merck & Co., Inc. (NYSE:MRK) is included among the 11 Dogs of the Dow Dividend Stocks to Buy Now. A close-up of a person's hand holding a bottle of pharmaceuticals. Merck & Co., Inc. (NYSE:MRK) has faced stock pressure due to its reliance on Keytruda but is diversifying. On July 9, Merck announced it would acquire UK biotech Verona Pharma for $10 billion, adding Ohtuvayre, a promising COPD treatment approved last year, to its portfolio. Ohtuvayre has had a strong launch and is being studied for more uses. Some analysts predict its sales could reach $4 billion, potentially making it another blockbuster for Merck. In its first quarter earnings, Merck & Co., Inc. (NYSE:MRK) highlighted that it began the year with strong progress, driven by growing contributions from its recently commercialized medicines and vaccines, along with ongoing advancements in its pipeline. It is focused and determined to fully capitalize on near-term opportunities while swiftly advancing the next wave of innovations that will improve patient outcomes and create long-term value for all stakeholders. Merck & Co., Inc. (NYSE:MRK) is also popular because of its dividend growth history, which spans 16 consecutive years. Currently, the company offers a quarterly dividend of $0.81 per share and has a dividend yield of 3.82%, as of July 26. While we acknowledge the potential of MRK as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and Disclosure: None. Fehler beim Abrufen der Daten Melden Sie sich an, um Ihr Portfolio aufzurufen. Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten
Yahoo
a minute ago
- Yahoo
Dogs of the Dow: Why Amgen's (AMGN) Dividend Power Makes it a Standout Pick
Amgen Inc. (NASDAQ:AMGN) is included among the 11 Dogs of the Dow Dividend Stocks to Buy Now. A pharmacist filling a prescription for a complex drug developed by the company. Amgen Inc. (NASDAQ:AMGN) is on the hunt for its next breakthrough drug— a common pursuit among pharmaceutical companies looking to stay ahead of rivals, especially as biosimilar competition grows. The company boasts a robust pipeline, with dozens of ongoing programs that could result in future drug approvals and expanded uses for existing treatments. Thanks to its strong track record of innovation, Amgen has performed well for years, and that momentum is expected to continue. Amgen Inc. (NASDAQ:AMGN) also reported strong earnings in the first quarter of 2025. The company posted revenue of $8.15 billion, marking a 9.4% increase year-over-year. It benefited from strong global demand for its products. Management voiced optimism about its long-term growth prospects, supported by the success of recent product launches and encouraging Phase 3 trial outcomes for multiple treatments. Amgen Inc. (NASDAQ:AMGN)'s cash flow makes it one of the most reliable dividend stocks. The company generated $1.0 billion in free cash flow during the quarter, doubling the figure from the same period a year earlier. Operating cash flow rose to $1.4 billion from $0.7 billion in the prior year. The company also returned $1.3 billion to shareholders in the form of dividends. Amgen Inc. (NASDAQ:AMGN) offers a quarterly dividend of $2.38 per share and has a dividend yield of 3.11%, as of July 26. The company has raised its dividends every year since 2011, which places it among the best dogs of the Dow. While we acknowledge the potential of AMGN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
a minute ago
- Yahoo
Cardinals lose starting cornerback Starling Thomas to torn ACL
Cardinals cornerback Starling Thomas suffered a serious knee injury during Friday's practice. Tests revealed that Thomas has a torn ACL, according to Adam Schefter of ESPN. That almost certainly means he will miss the entire season. Originally an undrafted rookie out of UAB, Thomas spent training camp with the Lions in 2023 but didn't make their roster. The Cardinals claimed him on waivers and he played surprisingly well as a rookie and even better in his second season in 2024. Last year Thomas played in all 17 games, with 15 starts, and played the most snaps of any cornerback on the team. The Cardinals may now be in the market to pick up another cornerback, as they were counting on Thomas to play a big role this year. He's a big loss.
